ClinicalTrials.gg
WithdrawnNCT03377101Updated Aug 14, 2018

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

A Phase 2 interventional study of Copanlisib and Fulvestrant in Estrogen Receptor Positive, HER2/Neu Negative and Progesterone Receptor Positive, sponsored by National Cancer Institute (NCI). Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-14.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
change in study design.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 298 studies in Breast Neoplasms by National Cancer Institute (NCI) — 22 open to participants now, 44 under way, 5 of them phase 3. Breast Neoplasms · National Cancer Institute (NCI).

Enrollment
214th of 223
0 · median 39
Started
2018
with 8 others
Phase 2
99 of 298
5 open now
Registered
266th of 298
by date

Among the 298 studies in Breast Neoplasms by National Cancer Institute (NCI), this one is the 214th largest by enrollment of the 223 interventional ones that give a count, is one of 9 that started in 2018, is one of 99 in phase 2, and was the 266th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 298 studies in Breast Neoplasms by National Cancer Institute (NCI) are open now, in 2 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 298 studies in Breast Neoplasms by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This randomized phase II trial studies the side effects and how well fulvestrant and palbociclib with or without copanlisib work in treating patients with hormone receptor positive, HER2 negative, stage IV breast cancer. Fulvestrant, palbociclib, and copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the safety profile of fulvestrant + palbociclib + copanlisib (FPC) and determine the recommended phase II treatment dose (RPTD).

II. To determine if FPC is superior to fulvestrant + palbociclib (FP) using progression-free survival (PFS) as an endpoint.

SECONDARY OBJECTIVES:

I. To assess the objective response rate (ORR = partial response [PR] + complete response [CR]) and clinical benefit rate (CBR = PR + CR + stable disease [SD] >= 6 months) of FPC versus (vs.) FP.

II. To compare the median PFS between FPC and FP arms in the following subgroups: tumor PIK3CA/PTEN altered (PIK3CA mutation or PTEN mutation/PTEN loss) and tumor PIK3CA/PTEN not altered (wild type PIK3CA and PTEN and without PTEN loss).

TERTIARY OBJECTIVES:

I. To evaluate copanlisib pharmacokinetics (PK) when administered in combination with FP.

II. To assess the median PFS in the following molecularly defined subgroups treated with either FPC or FP: tumor PIK3CA mutation vs. not, tumor PTEN mutation/PTEN loss vs. not, circulating tumor (ct) deoxyribonucleic acid (DNA) PIK3CA mutation vs. not, ctDNA PI3K/PTEN mutation vs. not, and ctDNA ESR1 mutation vs. not.

III. To evaluate ctDNA mutations at baseline and over time for response predictors at baseline, and clonal evolution associated with treatment.

IV. To assess resistance mechanisms to FP and FPC at baseline and at disease progression.

V. To examine the molecular effects of FP and FPC on tumor and circulating markers.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive fulvestrant intramuscularly (IM) on days 1 and 15 of course 1 and day 1 of subsequent courses, palbociclib orally (PO) on days 1-21, and copanlisib intravenously (IV) over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.

ARM II: Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses and palbociclib PO on days 1-21. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 5 years.

03

Conditions studied

  • Estrogen Receptor Positive
  • HER2/Neu Negative
  • Progesterone Receptor Positive
  • Stage IV Breast Cancer AJCC v6 and v7

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have confirmed estrogen receptor (ER) and/or progesterone receptor (PR) positive, negative or non-amplified breast cancer that is stage IV, with measurable or non-; ER/PR positivity is defined as at least 1% positive or Allred score of at least 3
  • All patients must agree to provide archival tumor material for research and must agree to undergo research tumor before treatment if presence of easily accessible lesions (judged by the treating physician); for patients with bone only disease, or patients without easily accessible lesions for the baseline research biopsy, availability of archival tumor material (2 x 4-5 micron section unstained slides, plus 15-20 x 10 micron section unstained slides or a tumor rich block) from previous breast cancer diagnosis or treatment is required for PTEN and PIK3CA analysis
  • No more than 1 prior chemotherapy in the setting; there is no limit on prior lines of endocrine therapy; (for patients enrolling to the safety run-in portion of the study, prior fulvestrant, CDK4/6 inhibitor, and everolimus is allowed)
  • For patients enrolling to the randomized phase II portion of this study, demonstrated resistance to prior endocrine therapy in the metastatic setting is required; this is defined as:

    • Progressed on prior endocrine therapy in the metastatic setting or
    • on endocrine therapy or
    • Relapsed within 12 months of completing adjuvant endocrine therapy or
    • If received adjuvant CDK4/6 inhibitor, relapsed at least 2 years after completion of adjuvant CDK4/6 inhibitor
  • Washout from prior systemic anti-cancer therapy of at least 3 weeks or 5 half-lives of the drug before the start of study treatment; washout from prior radiation therapy of at least 2 weeks before the start of the study treatment
  • (ECOG) performance status =\< 2 ( >= 60%)
  • >= 1,500/mcL collected no more than 7 days before starting study treatment
  • >= 75,000/mcL collected no more than 7 days before starting study treatment
  • >= 8.0 g/dL collected no more than 7 days before starting study treatment
  • Total =\< 1.5 x institutional (=\< 3 x institutional upper limit of normal for patients with Gilbert syndrome) collected no more than 7 days before starting study treatment
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =\< 2.5 x institutional upper limit of normal (=\< 5 x institutional upper limit of normal for patients with liver involvement) collected no more than 7 days before starting study treatment
  • >= 40 mL/min/1.73 m\^2 according to the Modification of Diet in Renal Disease (MDRD) abbreviated formula collected no more than 7 days before starting study treatment
  • Lipase =\< 1.5 x ULN collected no more than 7 days before starting study treatment
  • (INR) and partial thromboplastin time (PTT) =\< 1.5 x ULN collected no more than 7 days before starting study treatment
  • Glycosylated hemoglobin () =\< 8.5% collected no more than 7 days before starting study treatment
  • (LVEF) >= 50%
  • Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that their medication dose and INR/PTT is stable
  • Prophylactic antiemetics may be administered according to standard practice; the routine use of standard antiemetics, including 5-HT3 blockers, such as granisetron, ondansetron, or an equivalent agent, is allowed as needed
  • Patients may be or premenopausal women
  • Women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after the last dose of copanlisib; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of copanlisib administration
  • For patients enrolling to the safety run-in portion of the study, a history of treated is allowed if there is no disease progression symptomatically and by imaging within 28 days prior to registration and if the patient is off
  • Ability to understand and willing to sign a written document

Exclusion criteria

Exclusion Criteria:

  • For patients enrolling to the randomized phase II portion of the study, prior treatment with a CDK4/6 inhibitor or fulvestrant, or a PI3K inhibitor in the setting is not allowed
  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1 with the exception of alopecia)
  • therapy is not allowed while on study
  • Patients who are receiving any other agents
  • Receiving anti-arrhythmic therapy (beta blockers or digoxin are permitted)
  • Patients with are not eligible for the randomized phase II portion of the study; for the safety run-in portion of the study, patients with progressive brain metastases should be excluded; for patients enrolling to the randomized phase II portion of the study, patients with a history of brain metastases should be excluded from this clinical trial
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to copanlisib, PI3K inhibitors, or other agents used in study
  • The concomitant use of strong inhibitors of (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and strong inducers of CYP3A4 (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. John's wort) are not permitted from 14 days prior to enrollment until the end of the study; other medications that are prohibited while on copanlisib treatment:

    • Herbal medications/preparations (except for vitamins)
    • Anti-arrhythmic therapy other than beta blockers or digoxin
  • Systemic therapy at a daily dose higher than 15 mg prednisone or equivalent is not permitted while on study; previous corticosteroid therapy must be stopped or reduced to the allowed dose at least 7 days prior to the computed tomography (CT)/magnetic resonance imaging (MRI) screening; if a patient is on chronic corticosteroid therapy, corticosteroids should be de-escalated to the maximum allowed dose before the screening; patients may be using topical or inhaled corticosteroids; short-term (up to 7 days) systemic corticosteroids above 15 mg prednisolone or equivalent will be allowed for the management of acute conditions (e.g., treatment non-infectious pneumonitis); the use of corticosteroids as antiemetics prior to copanlisib administration will not be allowed
  • Major surgical procedure or significant traumatic injury (as judged by the investigator) within 28 days before start of treatment, or have not recovered from major side effects, open within 7 days before start of treatment
  • Uncontrolled intercurrent illness, including but not limited to, symptomatic congestive heart failure (> [NYHA] class 2), unstable angina pectoris, new-onset angina, cardiac arrhythmia, uncontrolled hypertension despite optimal medical management, seizure disorder requiring medication, or psychiatric illness/social situations that would limit compliance with study requirements
  • Proteinuria >= grade 3 as assessed by a 24 hour [h] protein quantification or estimated by urine protein: creatinine ratio > 3.5 on a random urine sample
  • Myocardial infarction \< 6 months before start of treatment
  • History of bleeding diathesis; any hemorrhage or bleeding event >= grade 3 within 4 weeks prior to the start of study medication
  • History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function
  • History of having received an allogeneic bone marrow or organ transplant
  • Patients with non-healing wound, ulcer, or bone fracture
  • Patients with active, clinically serious infections > grade 2 ( [CTCAE] version [v]4.0)
  • Patients with uncontrolled type I or II diabetes mellitus; uncontrolled diabetes is defined as > 8.5%
  • Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within 3 months before the start of study medication
  • Concurrent diagnosis of pheochromocytoma
  • Has undergone blood or transfusion \< 7 days prior to start of treatment
  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with copanlisib; these potential risks may also apply to other agents used in this study
  • (HBV) or (HCV); all patients must be screened for HBV and HCV up to 28 days prior to study drug start using the routine hepatitis virus lab panel; patients positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) will be eligible if they are negative for HBV DNA, these patients should receive prophylactic antiviral therapy; patients positive for anti-HCV antibody will be eligible if they are negative for HCV ribonucleic acid (RNA)
  • (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
  • Cytomegalovirus (CMV) polymerase chain reaction (PCR) positive at baseline
  • Patients with history of, or current disease are not eligible
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Arm I (fulvestrant, palbociclib)

    Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses and palbociclib PO on days 1-21. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.

    Drug: Fulvestrant · Other: Laboratory Biomarker Analysis · Drug: Palbociclib

  • Experimental
    Arm I (fulvestrant, palbociclib, copanlisib)

    Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses, palbociclib PO on days 1-21, and copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.

    Drug: Copanlisib · Drug: Fulvestrant · Other: Laboratory Biomarker Analysis · Drug: Palbociclib

Interventions

  • Given IV

    Also known as: BAY 80-6946, PI3K Inhibitor BAY 80-6946

  • Given IM

    Also known as: Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • Given PO

    Also known as: Ibrance, PD-0332991, PD-332991

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity based on the incidence, intensity, and duration of adverse events that are related to the drug combinations and occur according to according to National Cancer Institute Common Terminology Criteria for Adverse Event version 4.0

    Adverse events will be summarized by counts and percentages, overall as well as by does levels and by patient characteristics.

    Time frame: Up to 28 days

  2. Progression free survival (PFS)

    PFS probability will be estimated by the Kaplan-Meier (KM) product limit method and survival difference will be compared between the two arms by stratified log rank test. Hazard ratio (HR) with 95% confidence interval (CI) will be estimated between the two arms from the stratified Cox proportional hazard model, without and with adjustment for patient characteristics.

    Time frame: From the time on study to the time of disease progression or death or end of study, whichever earlier, assessed up to 5 years

Secondary outcomes

  1. Objective response rate defined as proportion of response-evaluable patients who achieve complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1

    Will be estimated with a 95% exact CI and difference between the two arms will be compared by Fisher's exact test. Raw and adjusted odds ratio (OR) will be derived with 95% CI from logistic regression without and with adjustment for patient characteristics.

    Time frame: Up to 5 years

  2. Clinical benefit rate defined as proportion of response-evaluable patients who achieve CR or PR or stable of disease (SD) according to RECIST v1.1

    Will be estimated with a 95% exact CI and difference between the two arms will be compared by Fisher's exact test. Raw and adjusted OR will be derived with 95% CI from logistic regression without and with adjustment for patient characteristics.

    Time frame: Up to 5 years

  3. Overall survival (OS) according to RECIST v1.1

    OS probability will be estimated by the KM product limit method and survival difference will be compared between the two arms by stratified log rank test. HR with 95% CI will be estimated between the two arms from the stratified Cox proportional hazard model, without and with adjustment for patient characteristics.

    Time frame: From time on study to time of death or latest follow-up, whichever earlier, assessed up to 5 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Aug 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2017
First posted
Dec 19, 2017
StartActual
Aug 7, 2018
Primary completionActual
Aug 7, 2018
CompletionActual
Aug 7, 2018
Last update
Aug 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03377101
Responsible party
Sponsor
First posted
Dec 19, 2017
Start date
Aug 7, 2018
Primary completion
Aug 7, 2018
Completion
Aug 7, 2018
Last update
Aug 14, 2018

Study contacts

Cynthia Ma
principal investigator · Duke University - Duke Cancer Institute LAO

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Copanlisib

Start the discussion